Evidence map›Paper›PMID 33420269›Full record

ArticleScientific reports2021

miR299a-5p promotes renal fibrosis by suppressing the antifibrotic actions of follistatin.

Neel Mehta, Renzhong Li, Dan Zhang, Asfia Soomro, Juehua He, Ivan Zhang, Melissa MacDonald, Bo Gao, Joan C Krepinsky

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Follistatin-mediated vascular protection via inhibition of activin A in essential and secondary hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Article
  4. Follistatin lowers blood pressure and improves vascular structure and function in essential and secondary hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Neel MehtaDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Renzhong LiDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Dan ZhangDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Asfia SoomroDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Juehua HeDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Ivan ZhangDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Melissa MacDonaldDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Bo GaoDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada.
Joan C KrepinskyDivision of Nephrology, Department of Medicine, McMaster University, Hamilton, Canada. krepinj@mcmaster.ca.
McMaster University · CASt. Joseph's Hospital · CA

Funding

CIHR MOP 136868
6 · The paper itself

Abstract

Caveolin-1 (cav-1), an integral protein of the membrane microdomains caveolae, is required for synthesis of matrix proteins by glomerular mesangial cells (MC). Previously, we demonstrated that the antifibrotic protein follistatin (FST) is transcriptionally upregulated in cav-1 knockout MC and that its administration is protective against renal fibrosis. Here, we screened cav-1 wild-type and knockout MC for FST-targeting microRNAs in order to identity novel antifibrotic therapeutic targets. We identified that miR299a-5p was significantly suppressed in cav-1 knockout MC, and this was associated with stabilization of the FST 3'UTR. Overexpression and inhibition studies confirmed the role of miR299a-5p in regulating FST expression. Furthermore, the profibrotic cytokine TGFβ1 was found to stimulate the expression of miR299a-5p and, in turn, downregulate FST. Through inhibition of FST, miR299a-5p overexpression augmented, while miR299a-5p inhibition diminished TGFβ1 profibrotic responses, whereas miR299a-5p overexpression re-enabled cav-1 knockout MC to respond to TGFβ1. In vivo, miR299a-5p was upregulated in the kidneys of mice with chronic kidney disease (CKD). miR299a-5p inhibition protected these mice against renal fibrosis and CKD severity. Our data demonstrate that miR299a-5p is an important post-transcriptional regulator of FST, with its upregulation an important pathogenic contributor to renal fibrosis. Thus, miR299a-5p inhibition offers a potential novel therapeutic approach for CKD.

Indexed as

AnimalsCaveolin 1FibrosisFollistatinGene Expression RegulationHumansKidneyMesangial CellsMiceMice, KnockoutMicroRNAsRenal Insufficiency, ChronicTransforming Growth Factor beta1Cav1 protein, mouseCaveolin 1FollistatinMicroRNAsMIRN299 microRNA, mouseTransforming Growth Factor beta1

Identifiers

PMID33420269
PMCPMC7794215
OpenAlexW3120850436

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.